How to Buy Mass Tort Leads: A Buyer's Guide for Law Firms

In single-event injury work, the market sells you a contact. Someone was hurt in a crash, they searched for a lawyer, and your intake converts them or does not. The qualification work is yours, it takes one phone call, and the cost of getting it wrong is one wasted lead.

Mass tort qualification is heavier, because a claimant is only viable if a specific product exposure can be tied to a specific diagnosis inside a specific window. So the market sells at three different depths, and the words are used loosely. A raw lead is an unscreened inquiry. A qualified lead is screened against the criteria that matter for that tort. A signed retainer means the vendor ran intake and obtained the fee agreement for you. Establish which one a quote refers to before you compare it to anything.

We sell the left column. Injury Lead Gen delivers exclusive qualified mass tort leads, not raw inquiries and not signed retainers, and the screening questions are built per campaign from the criteria you give us. Your firm keeps its own standard and its own client relationships. Campaigns, screening, and pricing by tort are on the mass tort leads page.

Where a tort sits in its lifecycle changes everything about the purchase: what a claimant costs, how long the money is tied up, and how much qualification risk you are absorbing. As of mid-2026 the picture looks like this.

• Talcum powder. The Johnson & Johnson litigation in the District of New Jersey remains the largest active MDL by volume, with more than 67,000 pending cases.
• Camp Lejeune is closed to new claims. The filing deadline under the Camp Lejeune Justice Act passed on August 10, 2024, and the Department of the Navy no longer accepts new claims or grants exceptions. More than 400,000 administrative claims were filed before it closed and settlement work continues, but no new claimant is eligible. Several lead vendors and AI summaries still list it as an active campaign. It is not one.
• GLP-1 drugs. Ozempic, Wegovy, and Mounjaro claims alleging gastroparesis and gallbladder injury run across two MDLs with roughly 3,900 combined cases and bellwether trials approaching.
• Bard PowerPort. MDL 3081, with more than 3,500 lawsuits and bellwether trials scheduled through 2026.
• Mesothelioma and asbestos. The longest-running toxic tort in the country, and one that never closes, because latency between exposure and diagnosis runs decades.
• AFFF firefighting foam. More than 10,000 claims were pending in the MDL as of May 2026, spanning both personal injury and water contamination claims.
• Roundup. Long-running and still generating filings, with a mature and correspondingly competitive acquisition market.
• Hair relaxer. Actively growing, with the Judicial Panel on Multidistrict Litigation continuing to transfer new cases through early 2026.
• Depo-Provera. Among the furthest along toward resolution. The parties told the court in June 2026 they had reached an agreement in principle on a settlement framework.

Read that list as a maturity curve rather than a menu. An early-stage tort offers cheaper acquisition and higher uncertainty about whether the science and the courts will hold. A late-stage tort offers clarity and a crowded, expensive acquisition market, and sometimes a registry or filing deadline that has already closed. Confirm the current posture of any tort directly before you commit budget, because these positions move quarter to quarter.

Our published price is $150 to $3,000 per exclusive mass tort lead. The spread is wide because the price tracks the tort rather than the state: a campaign with a broad eligible population and a common diagnosis costs a fraction of one that needs a narrow diagnosis inside a documented exposure window. Tell us which tort you are building and you get one number instead of a range. Campaign pricing is on the mass tort leads page.

Elsewhere in the market, costs are reported per signed retainer far more often than per lead, and published ranges disagree with each other violently. One widely cited set puts qualified leads at $15 to $75 and signed retainers at $200 to $800+. Another puts signed cases at $2,000 to $3,400 for the same named torts. Both are accurate. They are measuring different products.

The figures below are industry-reported costs per signed case from published 2024 to 2026 sources, at the documented end of that spectrum. Treat them as orientation rather than as a price list, and expect lower numbers wherever the unit is a bare signature.

Two patterns are worth internalizing. First, price tracks proof difficulty. Torts where the injury is rare and the causal link is well established command the highest acquisition costs because the qualified population is small. Second, price tracks competition. When a tort is heavily advertised, every buyer bids for the same finite pool of diagnosed claimants and the cost per signed case rises regardless of the underlying merits.

Three evidentiary elements decide whether a mass tort claimant is viable. Every serious intake operation in this space is built around them, and a provider who cannot speak to all three is selling you form fills.

1. Exposure. Where, how, and when the person encountered the product or substance. This includes duration and intensity, and for location-based exposure torts it means dates of residence or service that fall inside the statutory window.
2. Diagnosis. The specific medical condition, when it was diagnosed, current treatment status, and crucially whether records exist and can be obtained. A claimed condition with no retrievable record is not a case.
3. Timeline alignment. Whether the exposure and the onset of symptoms sit in the relationship the litigation recognizes. A diagnosis that predates the exposure, or falls outside the recognized latency period, fails regardless of how sympathetic the claimant is.

Around those three sit the ordinary checks: jurisdiction, statute of limitations position, and whether the claimant is already represented. Note that limitation analysis in these cases is frequently a discovery-rule question rather than a simple date subtraction, which is another reason diagnosis dates matter so much.

Build a triage path rather than sending everything to attorney review. Strong operators route weak files into a cheaper verification tier or decline them outright, and reserve lawyer time for files that have already cleared exposure and diagnosis. Attorney hours spent on unqualifiable claimants are the largest hidden cost in this category.

Three financial features separate mass tort from every other category in this cluster.

You fund the case for years before you collect

A single-event injury file might resolve in a year. A mass tort claimant acquired today may not produce a distribution until a settlement framework is negotiated, a claims administrator is appointed, and individual awards are processed. Practitioners describe carrying these cases for five to ten years, which means the budget that buys the claimants also has to feed the firm while they sit. That is a working capital problem, not a marketing problem, and it is the most common reason firms retreat from the category after their first campaign.

Volume is the point, and so is volume risk

The economics are built on aggregate recovery across a large inventory of qualified claimants. That structure rewards volume and it punishes a qualification error, because the error does not cost you one file, it costs you the same fraction of every file you bought that month. Sampling and auditing your incoming claimants is not optional at this volume.

Co-counsel structures change who bears what

Many firms participate through co-counsel or referral arrangements with a firm that has the infrastructure to litigate the tort. That can be an efficient way in, but it introduces a fee division that has to satisfy your jurisdiction's rules on dividing fees between firms, typically requiring the client's informed written agreement and either a proportional split or joint responsibility, with the total fee remaining reasonable. Settle the structure and the paperwork before the first claimant signs, not after.

Every purchased lead carries two compliance questions: whether you may buy it, and whether you may contact it. Mass tort raises the stakes on both because the advertising is high-volume, highly visible, and closely watched.

On the buying side, the analysis is the one set out in can lawyers buy personal injury leads. A generator selling advertising contacts is treated differently from a service that recommends a specific lawyer, and a flat fee is treated differently from a share of the recovery. Those distinctions do not change because the case type is a mass tort, but the volume means an error repeats across a whole campaign.

On the contacting side, documented consent is the whole defense, and the standard is set out in TCPA compliance for injury leads. Ask any mass tort provider to show you the consent language a claimant agreed to, the timestamp, and the page it appeared on. Claimants acquired through long chains of resale are precisely the files where that record tends to be missing, and a claimant who cannot be shown to have asked for legal contact is a liability rather than an asset.

The general vendor evaluation process in how to buy personal injury leads still applies. These five steps are what mass tort adds on top.

• Buying on unit price. The headline cost per claimant is the least informative number in this market. Only cost per verified, filed case means anything.
• Claimants with no retrievable medical records. A self-reported diagnosis is a starting point, not a case. If records cannot be obtained, the file will not survive the first serious review.
• Entering a tort late without checking deadlines. Mature litigations carry registry, census, and filing deadlines that can foreclose new claims. Check the current posture before you buy into a crowded tort.
• Files with no consent trail. Multiply-resold contacts are where provenance goes missing. In a category built on volume, that risk compounds across every file you bought.
• Undocumented co-counsel arrangements. Fee division between firms has rules. Agree the structure and the client disclosures before the first retainer is signed.